The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHargreaves Lansdown Regulatory News (HL.)

Share Price Information for Hargreaves Lansdown (HL.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 812.00
Bid: 814.20
Ask: 817.80
Change: 3.60 (0.45%)
Spread: 3.60 (0.442%)
Open: 812.00
High: 836.60
Low: 811.80
Prev. Close: 808.40
HL. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to the FSA's Consultation Paper CP12/12

27 Jun 2012 10:06

RNS Number : 2479G
Hargreaves Lansdown PLC
27 June 2012
 



Hargreaves Lansdown notes the FSA's Consultation Paper CP12/12 ("The Platform Consultation Paper") published on 27th June 2012.

 

The Financial Services Authority's (FSA) Platform Consultation Paper builds on earlier messages given by the FSA that they wish to proceed with a ban on Platforms being remunerated by fund groups. The FSA's position does not come as a surprise, and our planning has been focussed on a "no payments to Platforms" outcome.

 

The latest Paper is a consultation paper and clarity will not be available until the FSA issues a final Policy Statement. We firmly believe our business model is flexible enough to deal with any changes we may need to make when the FSA finalise their rules. We are confident we have solutions that will work for our clients.

 

We note that the FSA intends to confirm new platform rules before 31 December 2012 but not introduce them until 31st December 2013. We welcome the fact FSA has clarified the timescale for any changes to rules governing the platform market. This reduces the regulatory uncertainty that Platform firms have faced to date whilst also giving adequate time to prepare. 

 

We will continue to engage with the FSA during the consultation period. We do not anticipate announcing any changes to our business or our charges until after clarity is provided in the final policy statement.

 

We note the FSA's comments and questions in the paper about potentially extending their principles on platform remuneration to cover other regulated firms such as Life Insurance Companies, rather than just focus on platforms. We welcome this as a positive step in considering consistency and a level playing field, and is an issue on which we have campaigned for some time.

 

We remain relaxed about the overall outcomes of the Retail Distribution Review. Whilst the RDR may have become rather over-complicated and drawn out, its original principles were laudable and it should hold no fears for companies with a loyal and satisfied client base. Investing directly is becoming increasingly popular, is already excellent value for clients and Hargreaves Lansdown remains the market leader in providing this service. Our most recent client satisfaction survey has just confirmed 98% of clients rate the Hargreaves Lansdown service as good, very good or excellent. We expect to be able to continue to deliver strong growth in assets under administration.

 

We have previously stated we expect prices for retail investing to continue to reduce gradually over time, which will be good news for retail investors. We believe this gradual reduction will be driven mainly by the efficiencies of technology and growing scale, and offset by volume increase in the market. We do not see this path altered particularly by RDR. We do not currently believe any potential changes to our business model to respond to the FSA's RDR proposals will materially affect our service levels or profitability given our strong client base, high asset retention and exceptional service levels. We have already developed alternative revenue and charging models that would be compliant with the FSA's proposals. Hargreaves Lansdown has historically successfully used a range of methods to earn income for facilitating a wide range of client investments on the Vantage service. 

 

Hargreaves Lansdown remains committed to offering retail investors the best prices, best service and best information. 

 

For further information please contact:

Hargreaves Lansdown +44 (0)117 3171638

Ian Gorham, Chief Executive

Danny Cox, Media Relations

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RSPGMGZVLNZGZZG
Date   Source Headline
1st May 20249:27 amRNSDirector Declaration
30th Apr 20247:00 amRNSTrading Statement
25th Apr 20242:43 pmRNSDirector Declaration
19th Apr 20241:56 pmRNSDirector/PDMR Shareholding
4th Apr 202411:24 amRNSDirector/PDMR Shareholding
7th Mar 20241:54 pmRNSDirector/PDMR Shareholding
28th Feb 20244:01 pmRNSDirector/PDMR Shareholding
27th Feb 20242:29 pmRNSDirector/PDMR Shareholding
26th Feb 20244:43 pmRNSDirector/PDMR Shareholding
23rd Feb 20244:05 pmRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSHalf-year Report
9th Feb 202412:10 pmRNSNotice of Results
6th Feb 202412:08 pmRNSDirectorate Change
1st Feb 20247:09 amRNSDirector Declaration
17th Jan 202412:03 pmRNSDirector Declaration
2nd Jan 202410:06 amRNSDirector Declaration
20th Dec 202312:50 pmRNSDirector/PDMR Shareholding
14th Dec 202312:06 pmRNSDirector Declaration
11th Dec 20237:17 amRNSDirector Declaration
8th Dec 20234:33 pmRNSResult of AGM
6th Dec 20238:10 amRNSDirector Declaration
29th Nov 20237:00 amRNSDirectorate Change
7th Nov 20231:54 pmRNSNotice of AGM
23rd Oct 20238:00 amRNSAnnual Financial Report
19th Oct 20237:00 amRNSTrading Statement
12th Oct 20234:10 pmRNSDirector/PDMR Shareholding
12th Oct 20234:09 pmRNSDirector/PDMR Shareholding
22nd Sep 20233:21 pmRNSDirector/PDMR Shareholding
21st Sep 20234:15 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFinal Results
1st Sep 20239:59 amRNSNotice of Results
19th Jul 20237:00 amRNSTrading Statement
17th Jul 20234:32 pmRNSDirectorate Change
10th Jul 202311:00 amRNSDirectorate Change
15th Jun 202312:13 pmRNSHolding(s) in Company
13th Jun 20231:00 pmRNSDirectorate Change
15th May 20234:51 pmRNSDirector/PDMR Shareholding
10th May 20234:01 pmRNSDirector/PDMR Shareholding
4th May 202311:00 amRNSDirector Declaration
4th May 20237:00 amRNSTrading Statement
25th Apr 20232:13 pmRNSDirector/PDMR Shareholding
1st Mar 202310:22 amRNSDirector/PDMR Shareholding
15th Feb 20237:00 amRNSHalf-year Report
27th Jan 202312:02 pmRNSDirector Declaration
23rd Jan 202310:10 amRNSNotice of Results
19th Jan 20233:33 pmRNSHolding(s) in Company
20th Dec 20222:01 pmRNSDirector/PDMR Shareholding
16th Dec 202211:05 amRNSDirector Declaration
8th Dec 20228:00 amRNSDirectorate Change
24th Oct 20223:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.